Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Background: Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated.Objective: We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the rea...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2456532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583967127109632 |
|---|---|
| author | Mario Valenti Luciano Ibba Sara Di Giulio Luigi Gargiulo Piergiorgio Malagoli Anna Balato Carlo G. Carrera Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Francesca Gaiani Francesco Loconsole Angelo V. Marzano Matteo Megna Alessandra Michelucci Luca Potestio Simone Ribero Antonio Costanzo Alessandra Narcisi |
| author_facet | Mario Valenti Luciano Ibba Sara Di Giulio Luigi Gargiulo Piergiorgio Malagoli Anna Balato Carlo G. Carrera Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Francesca Gaiani Francesco Loconsole Angelo V. Marzano Matteo Megna Alessandra Michelucci Luca Potestio Simone Ribero Antonio Costanzo Alessandra Narcisi |
| author_sort | Mario Valenti |
| collection | DOAJ |
| description | Background: Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated.Objective: We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. In particular, we evaluated 116 patients who developed the neoplasm before starting the biologic with a mean time from diagnosis of neoplasia to the first biologic dose of 8.31 years. We also assessed 20 patients who received a diagnosis of neoplasm during treatment with IL inhibitors after a mean time of 2.41 years from the start of the biologic with a cumulative incidence of 3.06 per 1000 individuals.Results: Three patients experienced neoplasm recurrence during treatment with IL inhibitors, which led to the discontinuation of these drugs. In our study, biologics have demonstrated safety and effectiveness as treatment options for patients with both a history of neoplasm and those with concurrent tumors. However, further investigation is needed, particularly through larger and longer multicenter studies. |
| format | Article |
| id | doaj-art-2d3368272893469d808800b7c7c195a5 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-2d3368272893469d808800b7c7c195a52025-01-28T01:18:49ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2456532Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)Mario Valenti0Luciano Ibba1Sara Di Giulio2Luigi Gargiulo3Piergiorgio Malagoli4Anna Balato5Carlo G. Carrera6Paolo Dapavo7Eugenia V. Di Brizzi8Valentina Dini9Francesca Gaiani10Francesco Loconsole11Angelo V. Marzano12Matteo Megna13Alessandra Michelucci14Luca Potestio15Simone Ribero16Antonio Costanzo17Alessandra Narcisi18Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDepartment of Dermatology, Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, Pisa, ItalyDepartment of Dermatology, Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, ItalyDepartment of Dermatology, University of Bari, Bari, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyDermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, Pisa, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyBackground: Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated.Objective: We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis. In particular, we evaluated 116 patients who developed the neoplasm before starting the biologic with a mean time from diagnosis of neoplasia to the first biologic dose of 8.31 years. We also assessed 20 patients who received a diagnosis of neoplasm during treatment with IL inhibitors after a mean time of 2.41 years from the start of the biologic with a cumulative incidence of 3.06 per 1000 individuals.Results: Three patients experienced neoplasm recurrence during treatment with IL inhibitors, which led to the discontinuation of these drugs. In our study, biologics have demonstrated safety and effectiveness as treatment options for patients with both a history of neoplasm and those with concurrent tumors. However, further investigation is needed, particularly through larger and longer multicenter studies.https://www.tandfonline.com/doi/10.1080/09546634.2025.2456532Anti-IL-23anti-IL-17psoriasisneoplasms |
| spellingShingle | Mario Valenti Luciano Ibba Sara Di Giulio Luigi Gargiulo Piergiorgio Malagoli Anna Balato Carlo G. Carrera Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Francesca Gaiani Francesco Loconsole Angelo V. Marzano Matteo Megna Alessandra Michelucci Luca Potestio Simone Ribero Antonio Costanzo Alessandra Narcisi Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) Journal of Dermatological Treatment Anti-IL-23 anti-IL-17 psoriasis neoplasms |
| title | Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_full | Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_fullStr | Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_full_unstemmed | Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_short | Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) |
| title_sort | safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms a multicenter retrospective study il pso italian landscape psoriasis |
| topic | Anti-IL-23 anti-IL-17 psoriasis neoplasms |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2456532 |
| work_keys_str_mv | AT mariovalenti safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT lucianoibba safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT saradigiulio safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT luigigargiulo safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT piergiorgiomalagoli safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT annabalato safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT carlogcarrera safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT paolodapavo safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT eugeniavdibrizzi safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT valentinadini safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT francescagaiani safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT francescoloconsole safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT angelovmarzano safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT matteomegna safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT alessandramichelucci safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT lucapotestio safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT simoneribero safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT antoniocostanzo safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT alessandranarcisi safetyofinterleukininhibitorsinpatientswithplaquepsoriasisandhistoryofneoplasmsamulticenterretrospectivestudyilpsoitalianlandscapepsoriasis |